Suppr超能文献

质粒DNA/阳离子脂质体复合物的物理化学和药代动力学特性

Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes.

作者信息

Mahato R I, Kawabata K, Nomura T, Takakura Y, Hashida M

机构信息

Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.

出版信息

J Pharm Sci. 1995 Nov;84(11):1267-71. doi: 10.1002/jps.2600841102.

Abstract

The objectives of this study were (i) to characterize the plasmid DNA encoding the chloramphenicol acetyltransferase reporter gene (pCAT) complexed with cationic liposomes (Lipofectin and LipofectACE) in terms of particle size and zeta potential, (ii) to compare pharmacokinetic characteristics, and (iii) to study the hepatic uptake mechanisms. DNA/LipofectACE complexes showed a negative zeta potential of -36 mV at 1:5 w/w ratio, but a positive zeta potential of (19 mV at 1:10 w/w ratio. Lipofectin samples showed a positive zeta potential) of 21-28 mV at these ratios. These preparations showed a wide particle size distribution ranging from 600 to 1200 nm. Following intravenous injection of 1:10 w/w ratio [32P]pCAT/liposome complexes at a dose of 0.1 mg DNA/kg into the tail vein of mice, radioactivity was rapidly eliminated from the plasma and almost 50-60% of the dose was taken up by the liver within 5 min after administration. Plasmid DNA/liposome complexes were predominantly taken up by the liver nonparenchymal cells. The hepatic uptake was inhibited by preceding administration of dextran sulfate (DS), but not by polycytidic acid (poly[C]) and polyinosinic acid (poly[I]), suggesting the involvement of a phagocytic process. We suggest that these complexes are preferentially taken up by the liver nonparenchymal cells mainly via Kupffer cell phagocytosis.

摘要

本研究的目的是

(i)从粒径和zeta电位方面表征与阳离子脂质体(Lipofectin和LipofectACE)复合的编码氯霉素乙酰转移酶报告基因的质粒DNA(pCAT);(ii)比较药代动力学特征;(iii)研究肝脏摄取机制。DNA/LipofectACE复合物在1:5 w/w比例下显示出-36 mV的负zeta电位,但在1:10 w/w比例下显示出19 mV的正zeta电位。Lipofectin样品在这些比例下显示出21 - 28 mV的正zeta电位。这些制剂显示出6,00至1,200 nm的宽粒径分布。以0.1 mg DNA/kg的剂量将1:10 w/w比例的[32P]pCAT/脂质体复合物静脉注射到小鼠尾静脉后,放射性迅速从血浆中消除,给药后5分钟内几乎50 - 60%的剂量被肝脏摄取。质粒DNA/脂质体复合物主要被肝脏非实质细胞摄取。预先给予硫酸葡聚糖(DS)可抑制肝脏摄取,但多聚胞苷酸(poly[C])和聚肌苷酸(poly[I])则不能,这表明存在吞噬过程。我们认为这些复合物主要通过库普弗细胞吞噬作用优先被肝脏非实质细胞摄取。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验